Product Information
CIMETIDINE 300 MG TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.2358 per EA under NDC 00093819205. Its NADAC has been published 645 times since Nov 28, 2013.
FDA first approved this application on May 17, 1994. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the Cimetidine market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093819205
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CIMETIDINEApproval Type
Generic (ANDA)
FDA Application
ANDA074151FDA Approved
5/17/1994
TE Code
AB
On Market Since
11/24/2003
Pharmacological Classes
Price Statistics
The NADAC for CIMETIDINE 300 MG TABLET has been published 645 times since Nov 28, 2013, and over the history we have for it it has risen 45.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2358 per EA |
|---|---|
| All-time high | $0.3868 (Sep 14, 2016) |
| All-time low | $0.1500 (Sep 17, 2014) |
| 52-week high | $0.2705 |
| 52-week low | $0.2265 |
| Median price | $0.2911 |
| Average price | $0.2841 |
| Largest weekly change | +47.8% (Oct 21, 2015) |
| Weeks tracked | 645 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cimetidine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-2 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CIMETIDINE 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CIMETIDINE 300 MG TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $0.2358 per EA (NDC 00093819205), effective Sep 30, 2026.
How has the price of CIMETIDINE 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for CIMETIDINE 300 MG TABLET has risen 45.1%. It has been tracked across 645 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CIMETIDINE 300 MG TABLET?
Since Nov 28, 2013, the NADAC for CIMETIDINE 300 MG TABLET has ranged from a low of $0.1500 (Sep 17, 2014) to a high of $0.3868 (Sep 14, 2016), with a median of $0.2911 per EA.
Are there cheaper alternatives to CIMETIDINE 300 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as CIMETIDINE 300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures CIMETIDINE 300 MG TABLET?
CIMETIDINE 300 MG TABLET (NDC 00093819205) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.